Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy
- 7 May 2013
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 19 (5) , 691-697
Abstract
Summary: Recombinant factor VIII (rFVIII) products provide a safe and efficacious replacement therapy for prophylaxis and treatment of bleeding episodes in patients with severe haemophilia A. This multinational, open‐label, non‐controlled trial investigated the safety and efficacy of turoctocog alfa, a new rFVIII product. The primary objective was to evaluate safety. A total of 150 patients (24 adolescents and 126 adults) with severe haemophilia A (FVIII activity ≤1%), with at least 150 exposure days (EDs) to any FVIII product and no history of inhibitors were enrolled, and 146 patients (97%) completed the trial. All patients received prophylaxis with turoctocog alfa for approximately 6 months and had a mean of 85 EDs during the trial. None of the patients developed FVIII inhibitors, there were no indications of early FVIII inhibitor development and no safety concerns were identified. A total of 225 adverse events were reported in 100 (67%) patients, with the most common being events associated with dosing procedures, headaches, and nasopharyngitis. A total of 499 bleeding episodes were reported during the trial, the majority (89%) were controlled with 1–2 infusions of turoctocog alfa. Based on patient reports, the success rate (defined as ‘excellent’ or ‘good’ haemostatic response) for treatment of bleeding episodes was 81%. The overall median annualized bleeding rate was 3.7 (interquartile range: 8.7) bleeds/patient/year. In conclusion, turoctocog alfa provides a new, safe and effective alternative for prophylaxis and treatment of bleeding episodes in patients with haemophilia A.Keywords
This publication has 14 references indexed in Scilit:
- Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokineticsHaemophilia, 2013
- A randomized comparison of two prophylaxis regimens and a paired comparison of on‐demand and prophylaxis treatments in hemophilia A managementJournal of Thrombosis and Haemostasis, 2012
- Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®) - an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia AHaemophilia, 2011
- International comparative field study of N8 evaluating factor VIII assay performanceHaemophilia, 2011
- Functional characteristics of N8, a new recombinant FVIIIHaemophilia, 2010
- Purification and characterization of a new recombinant factor VIII (N8)Haemophilia, 2010
- Clinical evaluation of moroctocog alfa (AF‐CC), a new generation of B‐domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full‐length recombinant factor VIIIHaemophilia, 2009
- Practice patterns in haemophilia A therapy – global progress towards optimal careHaemophilia, 2006
- A postmarketing surveillance study of the safety and efficacy of ReFactoR (St Louis-derived active substance) in patients with haemophilia AHaemophilia, 2005
- Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin‐free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A1Haemophilia, 2004